

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Neurizon Therapeutics Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Marcus Hughes
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> Marcus Hughes is a beneficiary of the above holder which is the registered holder of the securities Ms Antoinette Quinlan Spouse of Marcus Hughes
Date of change	29 January 2026

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct</u></p> <ul style="list-style-type: none"> - 12,360,746 fully paid ordinary shares - 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032 <p><u>Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C></u></p> <ul style="list-style-type: none"> - 2,085,895 fully paid ordinary shares <p><u>Indirect – Ms Antoinette Quinlan</u></p> <ul style="list-style-type: none"> - 423,895 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	<p><u>Direct</u></p> <p>750,000 fully paid ordinary shares</p>
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.08 per Share (\$60,000.00)
No. of securities held after change	<p><u>Direct</u></p> <ul style="list-style-type: none"> - 13,110,746 fully paid ordinary shares - 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032 <p><u>Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C></u></p> <ul style="list-style-type: none"> - 2,085,895 fully paid ordinary shares <p><u>Indirect – Ms Antoinette Quinlan</u></p> <ul style="list-style-type: none"> - 423,895 fully paid ordinary shares

+ See chapter 19 for defined terms.

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in the Entitlement Offer as announced on 23 December 2025.
--	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.